Company / Financials
Eton Pharmaceuticals, Inc. Financials
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$31.6M
FY2025 · +48.9% YoY
Net Income
-$936.0K
FY2025 · +89.6% YoY
Profit Margin
-3.0%
FY2025 · net income / revenue
ROE
-3.8%
FY2025 · return on equity
Total Assets
$92.1M
FY2025
Total Debt
$21.8M
0.89x debt/equity
Equity
$24.4M
FY2025
ROA
-1.0%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score 0.63 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$31.6M+48.9% YoYNet Income HistoryProfit after all expenses and taxes-$936.0K+89.6% YoYGross Profit HistoryRevenue minus cost of goods sold$21.1M+47.1% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$10.6M+52.6% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$1.2M+85.6% YoYSG&A Expense HistorySelling, general, and administrative expenses$18.9M+1.9% YoYR&D Expense HistoryResearch and development spending$3.3M-16.9% YoYInterest Expense HistoryCost of borrowing and debt obligations$1.1M+11.0% YoYIncome Tax HistoryTotal income tax expense$247.0KEPS (Basic) HistoryBasic earnings per share-$0.04+88.9% YoY